Nausea and Vomiting Therapeutics is the fastest growing segment fueling the growth of Cancer Chemotherapy Market
The Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market |
The global Cancer Chemotherapy
Associated Nausea And Vomiting Therapeutics Market is estimated to be valued at
US$ 3,071.1 Mn in 2023 and is
expected to exhibit a CAGR of 5.7%
over the forecast period 2023 to 2030, as highlighted in a new report published
by Coherent Market Insights.
Market Overview:
Cancer chemotherapy associated
nausea and vomiting therapeutics are drugs that help reduce nausea and vomiting
due to chemotherapy. These drugs prevent and treat nausea and vomiting caused
by chemotherapy and help improve quality of life for cancer patients.
Market key trends:
One of the key trends in the
cancer chemotherapy associated nausea and vomiting therapeutics market is the
rise in oral fixed-dose combination drugs. Fixed-dose combination drugs deliver
multiple antiemetic agents in a single oral dosage form. This increases patient
compliance and convenience. Some examples of oral fixed-dose combinations are
Emend (aprepitant) capsules, SUSTOL (granisetron) extended-release injection,
and NEPA (netupitant-palonosetron) capsules. These drug combinations are
driving the growth of the market.
Segment Analysis
The global cancer chemotherapy
associated nausea and vomiting therapeutics market is dominated by the
antiemetics sub-segment, which accounts for nearly 60% share of the overall
market. The high adoption of antiemetics drugs for the prevention and treatment
of nausea and vomiting caused due to chemotherapy is the major factor
responsible for the dominant share of this sub-segment.
Key Takeaways
The Global
Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size
is expected to witness high growth, exhibiting CAGR of 5.7% over the
forecast period, due to increasing prevalence of cancer worldwide.
Regional analysis
North America region currently dominates
the global market and is expected to retain its dominance over the forecast
period. This is attributed to the growing number of cancer patients being
treated through chemotherapy and rising healthcare expenditure in the region.
Asia Pacific region is expected to witness the fastest growth rate over the
forecast period owing to increasing cancer awareness initiatives by public and
private organizations.
Key players
Key players operating in the
cancer chemotherapy associated nausea and vomiting therapeutics market are
Johnson & Johnson Services, Inc., Teleflex Incorporated, Cooper Surgical,
Inc., Genicon, Medtronic, B. Braun SE. The companies are focusing on developing
innovative treatment options to cater to the growing demand and consolidate
their market position. For instance, Johnson & Johnson Services, Inc.
launched Dificid in 2008 for treatment of Clostridium difficile-associated
diarrhea.
Read more
Comments
Post a Comment